Suresh Menon1, Feng Zhu2, Afsaneh Shirani2, Joel Oger2, Mark S Freedman3, Helen Tremlett2. 1. Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada/Division of Neurology, Department of Medicine, McMaster University, Hamilton, ON, Canada. 2. Division of Neurology, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada. 3. The Ottawa Hospital Research Institute and University of Ottawa, Ottawa, ON, Canada.
Abstract
OBJECTIVE: To examine disease progression in 'aggressive' multiple sclerosis (MS), British Columbia, Canada (1980-2009). METHODS: Aggressive (or 'malignant') MS was defined as Expanded Disability Status Scale (EDSS) ⩾6 within 5 years from onset. The first EDSS ⩾6 was termed 'baseline'. Within 2, 3 and 5 years post-baseline, patients were categorized as follows: 'worsened' or 'improved', relative to baseline EDSS (the remainder exhibited no change or had no new scores). The associations between patient characteristics (sex, relapsing onset/primary progressive, onset age, onset symptoms, disease duration, cumulative prior relapses and baseline EDSS) and worsening in disability were examined longitudinally using logistic regression. RESULTS: Of the 225/4341 (5.2%) aggressive/malignant MS patients, 134 (59.6%) were female, 167 (74.2%) were relapsing onset, 94 (41.8%) had received disease-modifying drugs at some point and the mean follow-up was 8.7 years. The proportion of patients who 'worsened' increased from 40.4% to 57.8%, while those who 'improved' varied little (range, 8.9%-10.2%). The odds of worsening increased with disease duration (adjusted odds ratio (AOR) = 1.36; 95% confidence interval (CI) = 1.22-1.52) and the presence of primary progressive (vs relapsing-onset) MS (AOR = 1.85; 95% CI = 1.01-3.38). CONCLUSION: Apart from disease duration and a primary progressive course, no clinically useful associations of subsequent disease worsening in patients with aggressive/malignant MS were identified.
OBJECTIVE: To examine disease progression in 'aggressive' multiple sclerosis (MS), British Columbia, Canada (1980-2009). METHODS: Aggressive (or 'malignant') MS was defined as Expanded Disability Status Scale (EDSS) ⩾6 within 5 years from onset. The first EDSS ⩾6 was termed 'baseline'. Within 2, 3 and 5 years post-baseline, patients were categorized as follows: 'worsened' or 'improved', relative to baseline EDSS (the remainder exhibited no change or had no new scores). The associations between patient characteristics (sex, relapsing onset/primary progressive, onset age, onset symptoms, disease duration, cumulative prior relapses and baseline EDSS) and worsening in disability were examined longitudinally using logistic regression. RESULTS: Of the 225/4341 (5.2%) aggressive/malignant MS patients, 134 (59.6%) were female, 167 (74.2%) were relapsing onset, 94 (41.8%) had received disease-modifying drugs at some point and the mean follow-up was 8.7 years. The proportion of patients who 'worsened' increased from 40.4% to 57.8%, while those who 'improved' varied little (range, 8.9%-10.2%). The odds of worsening increased with disease duration (adjusted odds ratio (AOR) = 1.36; 95% confidence interval (CI) = 1.22-1.52) and the presence of primary progressive (vs relapsing-onset) MS (AOR = 1.85; 95% CI = 1.01-3.38). CONCLUSION: Apart from disease duration and a primary progressive course, no clinically useful associations of subsequent disease worsening in patients with aggressive/malignant MS were identified.
Authors: J Das; J A Snowden; J Burman; M S Freedman; H Atkins; M Bowman; R K Burt; R Saccardi; C Innocenti; S Mistry; P J Laud; H Jessop; B Sharrack Journal: Mult Scler Date: 2021-02-10 Impact factor: 6.312
Authors: Igal Rosenstein; Sofia Rasch; Markus Axelsson; Lenka Novakova; Kaj Blennow; Henrik Zetterberg; Jan Lycke Journal: Front Immunol Date: 2022-08-10 Impact factor: 8.786
Authors: Ellen Iacobaeus; Georgina Arrambide; Maria Pia Amato; Tobias Derfuss; Sandra Vukusic; Bernhard Hemmer; Mar Tintore; Lou Brundin Journal: Mult Scler Date: 2020-06-12 Impact factor: 6.312
Authors: David Ellenberger; Peter Flachenecker; Firas Fneish; Niklas Frahm; Kerstin Hellwig; Friedemann Paul; Alexander Stahmann; Clemens Warnke; Paulus S Rommer; Uwe K Zettl Journal: Brain Date: 2020-12-05 Impact factor: 13.501